Predict your next investment

Corporate Venture
biogenidec.com

See what CB Insights has to offer

Investments

39

Portfolio Exits

16

Partners & Customers

3

About Biogen Idec New Ventures

Biogen Idec creates new standards of care in oncology, neurology and immunology. Asin the business of the development, manufacturing, and commercialization of novel therapies, Biogen Idecaims to transform scientific discoveries into advances in human healthcare.

Biogen Idec New Ventures Headquarter Location

14 Cambridge Center

Cambridge, Massachusetts, 02142,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Biogen Idec New Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Biogen Idec New Ventures in 1 Expert Collection, including Fortune 500 Investor list.

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

Latest Biogen Idec New Ventures News

True North Therapeutics bags $22 mln Series A

Jun 17, 2014

June 17, 2014     0 Comments South San Francisco-based biotech firm True North Therapeutics has closed $22 million in Series A funding. The investors included Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures and Baxter Ventures. PRESS RELEASE SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–True North Therapeutics, a biotechnology company developing novel therapies that selectively inhibit the Complement system to treat rare diseases, announced today that it has completed a $22 million Series A equity financing. Proceeds from the financing will be used to advance True North’s lead drug candidate, TNT009, into clinical development, with the initiation of the first human clinical trial planned for early 2015. The total Series A round encompasses initial funds from the spin-out of True North Therapeutics from iPierian, Inc., announced in September 2013. Investors in the Series A financing include Kleiner Perkins Caufield & Byers, MPM Capital, SR One, Biogen Idec New Ventures, and Baxter Ventures. The Series A financing will provide True North with funding to complete Phase 1a and Phase 1b studies with TNT009, including evaluation of patients in a variety of autoantibody-driven rare diseases mediated by the Complement system. The company has completed preclinical studies showing ex vivo efficacy of TNT009, a first-in-class monoclonal antibody that selectively inhibits a target of the Classical Complement pathway. “True North is on the cutting-edge in the field of therapeutics to target the Complement system,” said Geeta Vemuri, PhD of Baxter Ventures. “TNT009 is a promising new approach that offers a truly significant advance for rare diseases that have no approved therapies today.” With TNT009, True North is focused on Complement-mediated rare diseases in the hematologic, renal and neurological therapeutic areas. TNT009 inhibits C1s, a member of the Complement family of plasma proteins, which, upon activation, triggers a powerful enzymatic cascade that destroys and removes pathogens from the circulation. Aberrant activation of the Complement system has been described in numerous autoimmune settings in which antibodies that attack self, known as autoantibodies, play a role in disease pathogenesis. “This financing provides us with a strong financial foundation and firmly validates our investors’ enthusiasm for the promise of TNT009 and the value of implementing a robust clinical program for multiple rare diseases,” said Nancy Stagliano, PhD, Chief Executive Officer of True North. “We have a tremendous opportunity to develop a first-in-class treatment for Complement-mediated diseases, and we aim to make a significant impact on patient care with our innovative therapeutic approach.” About TNT009 TNT009 is a first-in-class molecule developed to selectively inhibit C1s, a serine protease specific to the Classical Complement pathway of the immune system. TNT009 selectively inhibits the Classical Complement pathway, thereby preventing downstream disease processes involving phagocytosis, inflammation, and cell lysis. With a unique mechanism of action and high target specificity, TNT009 selectively inhibits disease processes in the Classical Complement pathway cascade while maintaining the important immune surveillance provided by the Alternative Complement Pathway and Lectin Complement Pathway. About True North Therapeutics True North Therapeutics is a biotechnology company developing novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company’s lead monoclonal antibody drug candidate, TNT009, offers a novel approach for treating Complement-mediated diseases by selectively inhibiting a target in the Classical Complement pathway. True North’s drug development programs are focused on Complement-mediated rare diseases in the hematologic, kidney transplant, dermatology and neurological therapeutic areas. True North Therapeutics is located in South San Francisco, California. For more information, please visit www.truenorthrx.com.

Biogen Idec New Ventures Investments

39 Investments

Biogen Idec New Ventures has made 39 investments. Their latest investment was in Xilio Therapeutics as part of their Series C on January 1, 2021.

CBI Logo

Biogen Idec New Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/21/2021

Series C

Xilio Therapeutics

$95M

Yes

4

6/23/2020

Series B - II

Sana Biotechnology

$481M

Yes

7

10/11/2019

Seed VC - II

Clear Creek Bio

$1.03M

No

1

6/21/2017

Seed VC

Subscribe to see more

$99M

Subscribe to see more

10

2/10/2016

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/21/2021

6/23/2020

10/11/2019

6/21/2017

2/10/2016

Round

Series C

Series B - II

Seed VC - II

Seed VC

Series A

Company

Xilio Therapeutics

Sana Biotechnology

Clear Creek Bio

Subscribe to see more

Subscribe to see more

Amount

$95M

$481M

$1.03M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

7

1

10

10

Biogen Idec New Ventures Portfolio Exits

16 Portfolio Exits

Biogen Idec New Ventures has 16 portfolio exits. Their latest portfolio exit was Xilio Therapeutics on October 22, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/22/2021

IPO

$99M

Public

10

2/4/2021

IPO

$99M

Public

22

8/24/2020

Reverse Merger

$99M

8

11/18/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

12/14/2018

Asset Sale

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/22/2021

2/4/2021

8/24/2020

11/18/2019

12/14/2018

Exit

IPO

IPO

Reverse Merger

Acquired

Asset Sale

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Subscribe to see more

Subscribe to see more

Sources

10

22

8

10

10

Biogen Idec New Ventures Partners & Customers

3 Partners and customers

Biogen Idec New Ventures has 3 strategic partners and customers. Biogen Idec New Ventures recently partnered with ColumbiaDoctors on January 1, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

1/9/2015

Partner

United States

Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research. – Sequencing Facility and Shared Postdoctoral Program to Support Genetic Discovery Research to Advance Development of New Treatments –.

The agreement will integrate genomics research conducted at Columbia with Biogen Idec 's understanding of disease mechanisms and pathways , and expertise in discovering new medicines .

1

7/25/2011

Licensor

United States

Subscribe to see more

Subscribe to see more

10

1/1/1995

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

1/9/2015

7/25/2011

1/1/1995

Type

Partner

Licensor

Partner

Business Partner

Country

United States

United States

United States

News Snippet

Biogen Idec and Columbia University Medical Center to Conduct Collaborative Genetics Research. – Sequencing Facility and Shared Postdoctoral Program to Support Genetic Discovery Research to Advance Development of New Treatments –.

The agreement will integrate genomics research conducted at Columbia with Biogen Idec 's understanding of disease mechanisms and pathways , and expertise in discovering new medicines .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Biogen Idec New Ventures Team

13 Team Members

Biogen Idec New Ventures has 13 team members, including current Chief Executive Officer, James C. Mullen.

Name

Work History

Title

Status

James C. Mullen

Chief Executive Officer

Current

Eckhard Pfeiffer

Chief Executive Officer, President

Current

Paul Clancy

Chief Financial Officer

Current

Caroline Dorsa

Chief Financial Officer

Current

Peter N. Kellogg

Chief Financial Officer

Current

Name

James C. Mullen

Eckhard Pfeiffer

Paul Clancy

Caroline Dorsa

Peter N. Kellogg

Work History

Title

Chief Executive Officer

Chief Executive Officer, President

Chief Financial Officer

Chief Financial Officer

Chief Financial Officer

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.